Related Experiment Video

Updated: Oct 30, 2025

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

884

Classification of Non-Small Cell Lung Cancer's Tumor Immune Micro-Environment and Strategies to Augment Its Response

Alexander Chi1,2, Xia He2, Lin Hou3

  • 1Department of Radiation Oncology, Beijing Chest Hospital, Capital Medical University, Beijing 101100, China.

Cancers
|July 2, 2021
PubMed

Insights

Immune checkpoint blockade (ICB) shows promise in non-small cell lung cancer (NSCLC). Understanding the tumor immune micro-environment (TIME) and its biomarkers is key to predicting and improving patient response to ICB therapy.

Area of Science:

  • Oncology
  • Immunology
  • Cancer Research

Background:

  • Immune checkpoint blockade (ICB) offers durable responses in a subset of advanced non-small cell lung cancer (NSCLC) patients.
  • Response to ICB is linked to the tumor immune micro-environment (TIME), including immune cell infiltration, checkpoint expression (e.g., PD-L1), and cytokine/chemokine profiles.

Purpose of the Study:

  • To review the classification of TIME subtypes in NSCLC.
  • To explore the correlation between TIME characteristics and ICB response.
  • To identify biomarkers for predicting ICB response and discuss strategies for improving outcomes in non-responders.

Main Methods:

  • Literature review focusing on TIME classification in NSCLC.
  • Analysis of biomarkers associated with TIME subtypes.
  • Exploration of treatment strategies to enhance ICB efficacy.

Main Results:

  • Different TIME subtypes exist in NSCLC, influencing ICB response.
  • Specific TIME characteristics and biomarkers correlate with clinical outcomes.
  • Strategies to overcome resistance in non-responsive TIME subtypes are being developed.

Conclusions:

  • TIME characterization is crucial for predicting ICB response in NSCLC.
  • Biomarkers of TIME can guide personalized treatment strategies.
  • Further research is needed to optimize ICB therapy for all NSCLC patients.
Keywords:
LUADLUSCNSCLCimmune checkpoint blockadetumor immune microenvironment

More Related Videos

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

10.8K
Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

5.3K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
783
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.1K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
5.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
586